



Embera NeuroTherapeutics to Present at the 2017 BIO Investor Forum

BOSTON, Mass. and SHREVEPORT, La. – October 13, 2017 – [Embera NeuroTherapeutics, Inc.](#), a specialty pharmaceutical company developing novel treatments for cocaine, nicotine, and other addictions, today announced that Robert (Bob) Linke, the Company's President and Chief Executive Officer, and Michael Detke, M.D., Ph.D., the Company's Chief Medical Officer, will present at the 2017 BIO Investor Forum on Tuesday, October 17, 2017 at 10:45 a.m. Pacific time. The conference is being held from October 17-18, 2017 at the Westin St. Francis Hotel in San Francisco, California.

About Embera NeuroTherapeutics

Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on treating a broad range of addictions where the major clinical challenge is a limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. www.emberaneuro.com

Contacts

Bob Linke, President and CEO
Embera NeuroTherapeutics, Inc.
617-719-9406
rlinke@emberaneuro.com

For Media:
MacDougall Biomedical Communications
Kari Watson or Kara Mazey, 781-235-3060
kwatson@macbiocom.com or kmazey@macbiocom.com